Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of SHP607 to prevent chronic lung disease in extremely premature infants
jRCT2071200076Phase 2Active, not recruiting
- Sponsor
- Takeda
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of mecasermin rinfabate in bronchopulmonary dysplasia (BPD) (3 arms), sponsored by Takeda. Primary endpoint: Time to final weaning off respiratory technology support (RTS). Started May 2019; status: active, not recruiting.
02
Drugs
mecasermin rinfabate
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on jRCT2071200076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200076.